Additionally, patients using OW sema T2D reduced their body weight significantly more than patients who used the DPP-4, SGLT-2, daily subcutaneous GLP-1 RA, once weekly subcutaneous GLP-1 RA and insulin medications tested in the trials [28]. This evidence concerns the gene INS and type 2 diabetes mellitus.